BioMarin Pharmaceutical Inc.
BMRN
$60.43
$1.903.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.87% | 12.39% | 18.36% | 19.36% | 17.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.87% | 12.39% | 18.36% | 19.36% | 17.97% |
| Cost of Revenue | 3.10% | -46.13% | -57.38% | -56.95% | -54.63% |
| Gross Profit | 15.36% | 69.70% | 95.72% | 104.27% | 99.38% |
| SG&A Expenses | 2.18% | -2.85% | -0.59% | 9.03% | 13.07% |
| Depreciation & Amortization | -55.18% | -50.47% | -59.08% | -44.43% | -30.47% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.02% | 2.73% | -1.89% | 2.68% | 6.55% |
| Operating Income | 37.22% | 80.98% | 202.31% | 207.01% | 155.26% |
| Income Before Tax | -10.94% | 73.53% | 181.25% | 184.09% | 187.31% |
| Income Tax Expenses | 16.25% | 129.69% | 334.30% | 371.57% | 449.31% |
| Earnings from Continuing Operations | -18.26% | 61.47% | 156.15% | 154.99% | 154.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.26% | 61.47% | 156.15% | 154.99% | 154.62% |
| EBIT | 37.22% | 80.98% | 202.31% | 207.01% | 155.26% |
| EBITDA | 26.68% | 58.77% | 136.68% | 131.42% | 96.66% |
| EPS Basic | -18.80% | 60.21% | 153.60% | 152.09% | 151.39% |
| Normalized Basic EPS | 35.01% | 76.73% | 188.16% | 193.13% | 160.71% |
| EPS Diluted | -18.99% | 62.63% | 158.99% | 157.25% | 157.15% |
| Normalized Diluted EPS | 37.88% | 79.51% | 192.87% | 194.09% | 158.25% |
| Average Basic Shares Outstanding | 0.93% | 1.02% | 1.10% | 1.15% | 1.17% |
| Average Diluted Shares Outstanding | -1.98% | -0.83% | 0.58% | 1.73% | 2.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |